SALAZOPYRIN Suppository Ref.[7793] Active ingredients: Sulfasalazine

Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom

Product name and form

Salazopyrin Suppositories.

Pharmaceutical Form
Suppository.

Qualitative and quantitative composition

Sulfasalazine EP 0.5 g.

Active Ingredient	Description
Sulfasalazine	Therapeutic benefit of sulfasalazine appears to be due to a local action of the sulfasalazine and its split product 5-aminosalicylic acid on the mucous membrane and deeper colonic structures.

List of Excipients
Povidone Adepa Solidus

Pack sizes and marketing

PVC/Polyethylene laminate moulds.

Marketing authorization holder

Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom

Marketing authorization dates and numbers

PL 00057/1042

12 August 2010

Drugs

Drug	Countries
SALAZOPYRIN	Austria, Australia, Canada, Estonia, Finland, Hong Kong, Croatia, Ireland, Malta, New Zealand, Poland, Singapore, Turkey, United Kingdom, South Africa

Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.